文献速递淋巴瘤

老年弥漫性大B细胞淋巴瘤患者一线R-CHOP治疗后的长期超额死亡与净生存

Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatment.
PubMed 文献 · Br J Haematol · 2023-02-22

该研究利用临床试验数据和相对生存方法,估计老年弥漫性大B细胞淋巴瘤患者一线R-CHOP治疗后的10年净生存率并描述超额死亡风险随时间及主要预后因素的变化。10年净生存率为65%[59;71],超额死亡风险在诊断后急剧下降,10年时接近零。体能状态、结外病灶数和血清乳酸脱氢酶与超额死亡风险强烈相关。

要点

  • 老年DLBCL患者一线R-CHOP后10年净生存率为65%[59;71]。
  • 超额死亡风险在诊断后急剧下降,10年时接近零。
  • 体能状态、结外病灶数和乳酸脱氢酶与超额死亡风险强烈相关。

核心结论

  • 老年DLBCL患者一线R-CHOP治疗后10年净生存率为65%[59;71],10年时超额死亡风险接近零,长期死亡率与一般人群相比无增加。

研究设计与样本

  • 利用临床试验数据和相对生存方法,采用柔性回归模型估计老年DLBCL患者一线R-CHOP治疗后的10年净生存率和超额死亡风险。

主要发现

  • 10年净生存率为65%[59;71]。
  • 柔性模型显示超额死亡风险在诊断后急剧下降。
  • 体能状态、结外病灶数和血清乳酸脱氢酶与超额死亡风险强烈相关,即使调整其他重要变量后仍如此。
  • 10年时整个人群的超额死亡风险非常接近零。
  • 结外病灶数是诊断后短期的重要预后因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the era of immunochemotherapy, data on the long-term prognosis of elderly patients diagnosed with a diffuse large B-cell lymphoma (DLBCL) are scarce. In this population and on the longer term, other-cause mortality is an important competing risk that needs to be accounted for. Using clinical trial data and relative survival approaches, we estimated the 10-year net survival (NS) and we described the excess mortality hazard (EMH) due (directly or indirectly) to the DLBCL, over time and according to main prognosis factors using flexible regression modelling. The 10-year NS was 65% [59; 71]. Using the flexible modelling, we showed that the EMH decreases steeply after diagnosis. The variables 'performance status', 'number of extra-nodal sites' and the serum 'lactate dehydrogenase' were strongly associated with the EMH, even after adjustment on other important variables. EMH is very close to zero at 10 years for the whole population, so DLBCL patients do not experience an increased mortality compared to the general population in the long term. The number of extra-nodal sites was an important prognostic factor shortly after diagnosis, suggesting that it is correlated with an important but unmeasured prognostic factor that would lead to this selection effect over time.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Belot A, Camus V, Portugues C, et al. Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatment. Br J Haematol. 2023. PMID: 36813551. doi:10.1111/bjh.18705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。